ARA-290

Overview

ARA-290 (also known by the generic name cibinetide) is derived from a specific region of erythropoietin (EPO), the hormone best known for stimulating red blood cell production. ARA-290 was engineered to isolate EPO's tissue-protective signalling from its blood-thickening (erythropoietic) effect.

Proposed Mechanism

Selectively activates the innate repair receptor — a distinct receptor complex from the classic erythropoietin receptor — producing tissue-protective and anti-inflammatory effects without erythropoietin's blood-thickening side effect.

Research Context

The key research distinction is that ARA-290 acts on the “innate repair receptor,” a different receptor complex from the one that drives red blood cell production. This means research on ARA-290 focuses specifically on tissue-protective and anti-inflammatory effects — particularly nerve-related pain — without the safety concerns associated with elevating red blood cell counts.

Evidence Status — Well-documented

Has been studied in human clinical trials for neuropathic pain associated with sarcoidosis.

ARA-290 is one of the more clinically advanced compounds in this index: it has been studied in registered human clinical trials for neuropathic pain associated with sarcoidosis, a specific inflammatory condition. This gives it a stronger human-evidence base than many peptides on this list, though it remains a research compound rather than an approved therapy.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.